Insider · CIK 0001992324

Savitz Ryan

Reports to the SEC for 1 company · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001992324

Forms 4 and 5

Insider transactions

31 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-09	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	+31.2K sh	$21.77	+$680K	31,249
2026-07-09	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−10.4K sh	$100.22	−$1.04M	20,895
2026-07-09	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−15.3K sh	$101.24	−$1.55M	5,566
2026-07-09	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−5,566 sh	$101.97	−$568K	0
2026-07-09	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	−31.2K sh	—	—	68,751
2026-04-09	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	+8,224 sh	$17.88	+$147K	8,224
2026-04-09	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−8,224 sh	$89.84	−$739K	0
2026-04-09	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	−8,224 sh	—	—	71,776
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	+74.4K sh	$8.44	+$628K	74,367
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	+40K sh	$17.88	+$715K	114,367
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−1,390 sh	$78.33	−$109K	112,977
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−21.8K sh	$78.86	−$1.72M	91,152
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−1,485 sh	$80.25	−$119K	89,667
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−800 sh	$81.36	−$65.1K	88,867
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−2,366 sh	$82.84	−$196K	86,501
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−59.8K sh	$83.90	−$5.02M	26,701
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−19.5K sh	$84.57	−$1.65M	7,232
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−7,232 sh	$85.54	−$619K	0
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	−74.4K sh	—	—	10,399
2026-03-31	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	−40K sh	—	—	80,000
2026-02-03	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, CFO & CBO	AAward	+150K sh	—	—	150,000
2025-12-04	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	+20K sh	$8.44	+$169K	20,000
2025-12-04	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−20K sh	$45.18	−$904K	0
2025-12-04	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	+20K sh	—	—	84,766
2025-09-23	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, CFO & CBO	AAward	+60K sh	—	—	60,000
2025-09-09	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	+20K sh	$8.44	+$169K	20,000
2025-09-09	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, CFO & CBO	SSale	−20K sh	$35.00	−$700K	0
2025-09-09	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, CFO & CBO	MExercise/Conversion	+20K sh	—	—	104,766
2025-02-03	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, CFO & CBO	AAward	+150K sh	—	—	150,000
2024-05-23	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, CFO & CBO	AAward	+100K sh	—	—	100,000
2024-01-24	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, CFO & CBO	AAward	+120K sh	—	—	120,000

Recent filings

Accepted (ET)
Jul 134
Savitz Ryan0001992324-26-000008
SEC(opens sec.gov)
Apr 104
Savitz Ryan0001992324-26-000006
SEC(opens sec.gov)
Apr 14
Savitz Ryan0001992324-26-000004
SEC(opens sec.gov)

Companies

Dianthus Therapeutics, Inc. /DE/EVP, CFO & CBODNTH

Address

C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR

NEW YORK, NY, 10036